Mutations in the transforming growth factor beta type II receptor (TGFβRII) gene have been detected in several human cancer types exhibiting microsatellite instability. Using intron primers previously reported for examination of the entire coding region of the TGFβRII gene, 29 sporadic gastric cancers were screened with non-radioactive single strand conformation polymorphism and subsequent DNA sequencing analysis. Mutations of the TGFβRII gene were detected in three out of 29 tumors (10%). Two cases showed deletions in a polyadenine tract in both alleles and was positively associated with replication error. One case had an insertion of GA dinucleotide sequence in one allele. Mutations of the TGFβRII gene were restricted to exon 3 and other coding regions were not affected. Loss of heterozygosity was detected by analyzing a polymorphic site in intron 2. Three out of nine (33%) informative cases, which were all of intestinal type and advanced cases, showed loss of heterozygosity but neither TGFβRII mutation nor replication error was found in these cases. Immunoreactivity of TGFβRII in tumor tissues was reduced to a different extent in the gastric cancer with genetically abnormal transforming growth factor. Although the numbers studied are small, homozygous (A) 10 deletion or loss of heterozygosity of TGFβRII is involved in tumorigenesis and progression of at least some part of sporadic gastric cancer.
Introduction
Mutations in the transforming growth factor beta type II receptor (TGFβRII) gene have been found in various human cancers, including colon (1-4), stomach (5) , and head and neck (6) . These and other observations are consistent with the hypothesis that TGFβRII is a tumor suppressor gene whose mutational inactivation is important in human carcinogenesis (7, 8) .
Mutations in the TGFβRII gene found to date cluster in domains IX and XI (codons 505-544) of the kinase region (3, 6, 9) and in two microsatellites at codons 125-128 (A) 10 and 532-534 (GT) 3 in colon, gastric and endometrial cancers with microsatellite instability (3, 5) . Most studies have analyzed either cancer cell lines or frozen tumor series that can generate cDNA for polymerase chain reaction (PCR)-based analysis. Mutation analysis of genomic level in primary tumors is indispensable to fully understand the biological significance of TGFβRII in carcinogenesis, and intron-based primers for mutation analysis of genomic DNA have become available recently (10, 11) . We used these reagents to screen genomic DNA samples from 30 sporadic colorectal cancers for TGFβIIR mutations. We found a case with a deletion in a polyadenine tract in exon 3 and a point mutation in the kinase domain located in exon 7; both cases displayed a replication error (RER)-positive phenotype (4) . By analyzing genomic DNA, 'two-hit' inactivation of the TGFβRII gene, deletion or insertion in (A) 10 tract and another mutation in a different allele have also been reported in colon tumors from patients with hereditary non-polyposis colorectal cancer (HNPCC) (12) . Accumulating evidence indicates that different kinds of cancers have characteristic patterns of mutations in the TGFβRII gene. Its mutation has been mostly associated with and is present in Ͼ90% of cases of a subgroup of colon cancers with RER (1, 3, (13) (14) (15) . RER-positive colon cancers characteristically inactivate TGFβIIR by acquiring insertions or deletions of one or two adenine base pairs in this repeat tract of adenines (1) . It is also reported (5) that these same TGFβIIR frameshift mutations were common in RER positive gastric cancers (five of seven cases) but were less common in RER-positive endometrial cancers (four of 24 cases); Ouyang et al. (16) also reported that although the incidence of RER was high in pancreatic cancer, no mutations in the TGFβRII were found, thereby suggesting that tissue-specific factors play a role in determining the generation or selection for these mutations (5) . Moreover, inactivation of TGFβRII has been reported in non-RER gastric cancer cell lines via gene deletion (17) .
Because previous investigations on the mutation of TGFβRII in gastric cancer have been based on analyses of cDNA level or genomic level, but have only focused on some particular regions, we thought it worthy to analyze the entire coding region at the genomic level to fully understand the manifestations and mechanisms of TGFβRII in gastric carcinogenesis. In this study, 29 sporadic gastric cancers were analyzed by PCR-single strand conformation polymorphism (SSCP) and DNA sequencing for mutations in the TGFβRII gene in genomic DNA samples, and we investigated the relationships with RER, loss of heterozygosity (LOH) and immunohistochemical findings.
Materials and methods

Tissue samples
Primary gastric cancers and corresponding normal tissues were obtained from 29 patients resected at the affiliated hospitals of Hamamatsu University School of Medicine, Shizuoka, Japan. The histological types include 10 well differentiated, seven moderately differentiated and eight poorly differentiated adenocarcinomas, three signet ring cell adenocarcinomas and one mucinous adenocarcinoma, which were diagnosed by WHO criteria (18) . Twenty-one tumors were of advanced stage with regional lymph nodes or distant metastases. Genomic DNA samples were isolated by proteinase K treatment and phenol chloroform extraction using standard protocols (19) .
PCR-SSCP analysis
All samples were examined for mutations in exons 1-7 of the TGFβRII gene by PCR-SSCP analysis. Using the intron primers designed by Takenoshita et al. (4) , PCR was accomplished with 50 ng of genomic DNA suspended in a total volume of 25 µl PCR reaction buffer containing 1ϫ Ex buffer, 0.1 mM deoxynucleotide triphosphate, 0.1 mM Mg(OAC) 2 , 0.1 mM primer and 0.5 U Takara Ex Taq DNA Polymerase (Takara, Osaka, Japan). The PCR conditions were as follows; 40 s at 94°C, 30 s at 55°C or 60°C, and 90 s at 68°C for 35 cycles, followed by 8 min at 68°C. Aliquots of 5-10 µl of each PCR product were then denatured, cooled on ice, loaded on neutral 8-10% polyacrylamide gels with and without 5% (vol/vol) glycerol, electrophoresed at room temperature or 4°C, silver-stained and dried (Silver Stain kit; Daiichi, Tokyo, Japan) as described previously (20) .
Sequence analysis DNA fragments with mobility shifts or extra bands were sequenced. Amplified DNA fragments were first purified by phenol-chloroform extraction and ethanol precipitation, loaded on 2% agarose gel electrophoresed at room temperature and further purified using a Qiaex II Gel Extraction Kit (Qiagen, Chatsworth, CA) and then cloned into the pGEM-T Vector using the TA Cloning System (Promega, Madison, WI) according to the manufacturer's protocol. Sequencing reactions were performed using the T7 Sequenase DNA polymerase and 7-deaza-dGTP (Amersham Life Science, Arlington Heights, IL). The sequence reaction samples were loaded on 6% denaturing polyacrylamide gels, electrophoresed, dried, and exposed to Kodak XAR film for 20-24 h at room temperature.
To circumvent a 'false' identification of mutations caused by misincorporation by polymerase, we duplicated PCR and SSCP in all cases. More than four clones were sequenced. When we could have two or more consistent mutated clones confirmed by sequencing bidirectionally, we defined that this case had a mutation.
Analysis of microsatellite instability (MI)
MI was determined using five or more of the microsatellite markers (at D1S116, D2S136, D5S82, D6S87, D17S261 and TP53). In each case, one of the primers was 32 P end-labeled, and paired DNAs of normal and cancerous tissues were amplified by PCR followed by electrophoresis in 5% polyacrylamide/7.6 M gels as described previously (21) . Nucleotide sequences of the primers and detailed conditions for PCR amplification of microsatellites have been reported elsewhere (4, 21) . Tumors with new bands at two or more of the microsatellite loci were defined as RER positive.
Loss of heterozygosity (LOH) analysis
LOH was evaluated by analyzing a frequent polymorphic site within intron 2 (12) . The exon 2 PCR product revealed an identifiable polymorphism by SSCP ( Figure 2 ).
Immunohistochemistry
Immunohistochemical identification of TGFβIIR and cyclin D1 in cancer and non-cancerous portions of resected specimens were performed. Polyclonal antibodies L21 and H567, which recognize amino acid 246-266 and 1-567 of TGFβRII respectively (Santa Cruz Biotechnology, Santa Cruz, CA), and monoclonal antibody cyclin D1 (clone DCS-6) (Novocastra, Newcastle, UK) were applied to microwaved dewaxed tissues. Specific immunoreactivity was detected with a streptavidin-biotin complex peroxidase system using diaminobenzidine as substrate as described elsewhere (22) . The sections were then counterstained with hematoxylin. Cytoplasmic staining of L21 for TGFβRII was considered positive as reported (23) and nuclear staining of cyclin D1 as seen in follicular lymphoma (positive control) was defined as positive. Antibody H567 was immunoreactive in cytoplasmic and nuclear regions of the epithelium.
Results
Mutation analysis
We examined all TGFβRII exons in 29 gastric cancers. Three cases gave a band shift in SSCP. Two had a deletion in the (A) 10 repeat: case A was a deletion of a single A and case B was two deletions of two and three adenines (Figure 1 ). Both cases had microsatellite instability. Both cases had mutations of the TGFβRII gene in both alleles: in case A, the intensity of a band corresponding to the wild-type allele was very faint in PCR-SSCP, which was presumably contributed by contaminating normal cells. In this case, the extra band was clearly visible. Sequencing of the PCR product showed that none of four randomly selected clones contained wild-type sequence, and the polymorphic site was heterozygous (a/g), which indicates both alleles exist and include the single adenine deletion. In case B, PCR-SSCP clearly showed two new bands as well as the wild-type band, which we attributed to normal stromal cells in the tumor sample. This case had deletions of both two and three adenines, which indicates that they were derived from different alleles of the TGFβRII gene. In case C, we had clones with a G:A dinucleotide insertion just upstream of (A) 10 as well as clones with a wild-type sequence, which indicates that only one allele of TGFβRII receptor had mutations in these bases. Alternately, the wild-type allele detected in this case may come from normal stromal cell contamination. This case was heterozygous (a/g) and showed neither RER nor LOH according to our RERϩ criteria, but one locus showed MI. Polymorphism analysis Three patterns of bands were noticed in exon 2 SSCP ( Figure  2 ). Sequencing showed that an a/g polymorphism at the seventh base of intron 2 was responsible for the polymorphism and the three types found in SSCP were a/a, a/g and g/g as observed by Lu et al. (12) . Among the 29 cases of gastric cancers, six were a/a types (21%), nine a/g types (31%) and 14 g/g types (48%) respectively. Three of the nine informative cases (a/g type) showed LOH of the TGFβRII gene (33%); all these were advanced stage and classified as intestinal type (Table I) .
Microsatellite instability
Of the 29 cases, four were RER positive (14%) at two or more loci. Among them, two cases showed deletions in the polyadenine (A) 10 tract of the TGFβRII (50%). These results were consistent with the results for gastric cancer reported previously. One case (case C), which showed only one MI, had a G:A dinucleotide insertion just upstream of the poly- 
a Cyclin D1, L21 and H567 represent antibodies used in this study. b Immunoreactivity is graded as Ϫ/ϩ (negative or faint), ϩ (moderately positive),ϩϩ (equal to positive control), ϩϩϩ overexpression. c,d Positive and negative portions of L21 and H567 in tumor are located in the same region. In case A, 70% area of the tumor exhibits faint positivity and 30% moderate positivity; in case C, 10% area of the tumor exhibits faint, 70% moderate and 20% strong positivity.
adenine tract. In our data set, all the cancers with MI and/or associated (A) 10 deletion [four out of four cases with MI positive and two out of two cases with (A) 10 deletion] were located in the lower part of the stomach (Table I) . But the case with G:A dinucleotide insertion, which showed only one MI, was located in the proximal part of the stomach, and this may indicate a different mechanism of carcinogenesis.
Immunohistochemistry of TGFβRII
The fundic glands of the stomach were always immunoreactive and were consequently used as a positive control. Nontumorous gastric foveolar epithelium was weakly positive for L21 and H567. We compared these mutations found in our series with immunologically identifiable inactivation or downregulation of TGFβRII expression in gastric cancer cells. In cases with TGFβRII mutations, the immunoreactivity to TGFβRII recognized by L-21 and H567 was reduced to a different extent (Table II) . In cases with (A) 10 tract mutations of TGFβRII, two case showed reduction of the immunoreactivity to TGFβRII recognized by L21 and H567 ( Figure 3A ), but one had little change. On the other hand, in some cases without mutation or LOH, reduced immunoreactivity was clearly demonstrated, which indicates other mechanisms are also involved. In one of the cases with LOH, immunoreactivity was demonstrated in the tumor cells ( Figure 3B ). The staining profile of these antibodies in the cases with genetic alterations of TGFβRII is summarized in Table II . There were only scattered and faint nuclear staining in a small number of cells in the gastric mucosa for cyclin D1.
Discussion
Recent studies have provided evidence that is consistent with the hypothesis that the TGFβRII gene is a tumor suppressor in several types of human cancers (1) (2) (3) 8) , and it is generally believed that its inactivation is tightly associated with RER.
In this report, we examined the genomic status of TGFβRII in primary gastric carcinoma. One of our aims was to see whether there is any mutation that affects TGFβRII function outside the (A) 10 repeat. We also wanted to see whether the so-called two-hit mechanism outside the (A) 10 region was involved in inactivation of TGFβRII in gastric cancers, as reported in HNPCC (12) . Previous studies on the TGFβRII mutation in gastric cancer have been based on the analysis of cDNA products or genomic DNA, and have only focused on some particular regions. To further characterize the role of the TGFβRII gene in carcinogenesis of sporadic gastric cancer, we analyzed the entire coding sequence of the TGFβRII gene in 29 cases of sporadic Japanese primary gastric cancer by using previously designed intron-based primers (4) .
At first, as with most investigators, we attempted to use DNA samples extracted from paraffin-embedded tissues because of 1542 the rich available resources, but this kind of DNA sample was often unsuccessful for amplification by most of our designed intron primers. Therefore, we had to use the limited DNA samples extracted from frozen tissues.
In this study, three cases were found to have a frameshift mutation in the (A) 10 repeat tract of TGFβRII (10%), but no mutation was found outside this region, which indicates that the (A) 10 repeat tract is the main target of TGFβRII mutation in sporadic gastric cancer: other coding sequences are rarely affected. Moreover, two of three cases had mutations in the (A) 10 repeat tract of both alleles, which suggests that the homozygous mutations (mutations in both alleles) of TGFβRII are common in the carcinogenesis of sporadic gastric cancer. Lu et al. reported frequent genetic changes in both alleles in HNPCC (12) [heterozygous deletions in the (A) 10 repeat of the TGFβRII gene and an additional missense mutation]. They described this heterozygous deletion in the (A) 10 repeat plus somatic mutation as two-hit inactivation. In our series, homozygous deletion in the (A) 10 repeat tract was frequently found and may reflect another two-step inactivation. In case B, sequencing showed that one allele had 3-A deletions in the (A) 10 repeat tract, which has not been reported previously.
For the relationship between mutation of TGFβRII and RER, we found four of 29 cases with RERϩ (14%) based on our criteria, and among them two cases had frameshift mutations in the (A) 10 repeat tract (50%). Seemingly, incidence of RERϩ and its related TGFβRII mutation was lower than that reported by others (15-38%) (5, (24) (25) (26) (27) . We presume these discrepancies might result from different RER criteria, and selection of number and types of microsatellite markers, patient and cancer types, and DNA origin (from paraffin or frozen tissue), etc. For example, as far as RERϩ criteria are concerned, some researchers have chosen ജ1 loci microsatellite marker that showed MI as RERϩ (24, 25) , but recent study has indicated only one locus or even two loci, which shows that MI is not an appropriate indicator of mutator phenotype criteria (27) . Therefore, some investigators chose eight of 11 loci that showed MI as a phenotype mutator criterion (27) . We adopted ജ2 loci (out of four loci) that showed MI as a RERϩ criterion. We think our criteria, DNA origin and case selection, are close to that of Nakashima et al.'s report (26). Our RERϩ incidence was similar to theirs (15%). However, these criteria might risk missing some cases that have a real mutator phenotype. In our case C, which showed a GA dinucleotide addition just upstream of (A) 10, only one locus had MI, and this might be considered a mutator phenotype that escaped our criteria. If this case is included as an RERϩ category, the RERϩ incidence should be 17%, and three of five cases with RERϩ showed frameshift mutations in the (A) 10 repeat tract of TGFβRII (60%). On the other hand, in our RERϩ without mutation of TGFβRII, there is a possibility that some of them might not be genuine mutator phenotypes as indicated in Chung's report (27) . Alternately, we cannot exclude the possibility that there may be another mutational mechanism for the genetic change in addition to deficient mismatch repair (MMR) in case C.
The prevalence of the a/g polymorphism in intron 2 of the TGFβ II receptor has not been previously described. Although the biological significance of this polymorphism is unclear, the distribution in gastric cancer in our series was different from that in healthy controls (data not shown), although rigorous statistical analysis will require more cases.
The TGFβRII gene has been mapped to chromosome 3p22 (28) , where deletions commonly occur in several tumors (29, 30) but are rare in colon cancers (12, 31) . In gastric carcinoma, frequent LOH on chromosomes 1q, 5q 7q, 12q, 17p and 18q has been reported (32-38), but there have been no reports concerning LOH of 3p in gastric cancer. Using the polymorphism inside the TGFβRII gene, we found LOH in three of nine informative cases, all of which were at an advanced stage and histologically classified as intestinal type, which indicates that LOH in the TGFβRII might be associated with progression of gastric cancer rather than an early event in gastric carcinogenesis. In many tumor suppressor genes, one allele is inactivated by deletion and the other allele is inactivated by point mutation. However, we could not observe this mode of inactivation in TGFβRII because mutation was not detected in the remaining allele in the cases with LOH.
We compared these mutations and LOH of TGFβRII found in our series with immunologically identifiable inactivation or downregulation of TGFβRII expression in gastric cancer cells. In cases with TGFβRII mutations, the immunoreactivity to TGFβRII recognized by L-21 and H567 was reduced to a different extent (Table II) but did not completely disappear. In case C, GA insertion had been also expected to generate a truncated protein, but the reduction in immunoreactivity was not remarkable. In this case, the remaining wild-type allele was present and this may explain why the reduction of immunoreactivity was not dramatically detected. Another explanation could be the possible heterogeneity of TGFβRII mutation in the tumor tissue. The heterogeneity of immunoreactivity in the tumor is also consistent with this idea. Alternatively there might also be a cross-reactivity to the other cellular proteins. The lists of proteins that have homology with the immunogenes used (data not shown) include other kinds of receptor protein kinase that are known to be overexpressed in gastric cancer (39) . In cases with LOH of TGFβRII, five cases showed reduction of the immunoreactivity to TGFβRII recognized by L21 and H567, but one had no change; on the other hand, in some cases without mutation or LOH, reduced immunoreactivity was clearly demonstrated, which indicates that other mechanisms might also be involved in inactivating the expression of TGFβRII. Alterations of the TGFβRII gene may be related to reduction of immunoreactivity, but not vice versa. Park reported that reduced expression did not lead to genetic alteration of this gene in cell lines (17) . Our observation is consistent with a recent report of thyroid cancer (23) , which found no genetic alteration in the cases with underexpression of this gene. DNA methylation may also be involved with TGFβRII inactivation. Furthermore, absence of overexpression of cyclin D1 in cases with TGFβRII alteration is also compatible with the previous report that cyclin D1 downregulates the TGFβIIR receptor gene expression in an in vitro system (40) . In the A431 cell line, the mutation in the promoter region of TGFβIIR inactivates this gene.
In summary, our results suggest that the frequency of TGFβRII mutation is relatively low in sporadic gastric cancer and the alterations are almost limited to the (A) 10 repeat tract, which are tightly associated with RER. LOH was found in 30% of informative cases, but was not associated with heterozygous mutation of (A) 10 repeat tract or RER. Homozygous deletion of (A) 10 repeat tract, rather than heterozygous deletion plus LOH, is involved in the process of carcinogenesis in sporadic gastric cancer. Very recently, Wang et al. reported frequent mutations outside the (A) 10 region in head and neck cancer, although they did not investigate the entire coding region (41) . Considering the striking difference in the profile of the mutations in TGFβRII among various human tumors, our observations, based on a survey of the entire coding sequence, show one of the characteristics of human gastric cancer.
